Templeton u-turn has no bearing on Sun-Taro case

Asset manager withdraws from Israeli drug co's appeal. Global asset management firm Templeton had dissented to Sun Pharma's $454-million proposal to acquire Israeli drug-maker Taro, ever since the deal was formalised in .